consisting of G 12 and G 13 , activates the small G protein Rho pathways. The G q family, including G q , G 11 , G 14 , and G 16 , is linked to the stimulation of phospholipase C␤ (PLC␤) isoforms that trigger the Ca 2ϩ signal cascade (7, 31) . As part of GPCR screening, many attempts have been made to design universal outputs so that any ligand-GPCR response can be screened at a common end point. Although several assays have been established, most of them are limited to the evaluation of a selective G␣ subfamily and thus do not allow a comprehensive screening of orphan GPCRs that do not have a known downstream signaling pathway. Interestingly, it has been shown that pertussis toxin prevents some G i members from interacting with GPCRs by ADP ribosylating the Cys residue at the COOH-terminal fourth position (40) . This early clue led to the discovery that the COOH-terminal region of the G␣ subunit dictates the specificity of interaction with receptors (8, 9) . Several chimeras using the G q backbone with G i COOHterminal replacements have offered convenient assays for G icoupled GPCRs to overcome the difficulty and low sensitivity of traditional G i assays during the large-scale screening (41) . Furthermore, a series of chimeras incorporating different length of the G z COOH terminus into the backbone of G 16 have also been designed for ligand screening (26) . Nevertheless, despite the promiscuous characteristics of G 16 to interact with a variety of GPCRs, many GPCRs have failed to activate G 16 or its chimeras (26) . Therefore, until now, no single G␣ or chimera can truly couple to all the different receptors. The unique characteristic of each G␣ COOH terminus, providing a limited range on receptor selectivity, suggests that it is necessary to screen the whole G␣ spectrum when studying an orphan GPCR without known G␣ pathways.
In addition, it has been known that an activated GPCR can couple to several G␣ proteins simultaneously (29). However, current G q , G 12 , and G i readouts are only able to reflect the compound responses shared by several G␣ members in the same family or across subfamilies and are inadequate to dissect the GPCR responses into each individual G␣. In contrast, a cAMP increase resulting from the stimulation of adenylyl cyclases has been set up as a direct effect of the G s ␣. Therefore, we hypothesized that the G s pathway would be a superior system if designed to dissect and screen GPCR signals. To further cover the COOH-terminal varieties of the different G␣ subfamilies, a set of chimeric G s proteins where the COOH termini were replaced with those of other known G␣ for diverse GPCR interactions were constructed. We showed that these chimeras were able to reveal previously unknown G protein-coupled pathways for a given GPCR with a known ligand. Moreover, the present chimeric G proteins are able to serve as a tool to investigate the potential G protein pathways of orphan GPCRs, thus allowing the future screening of candidate ligands.
MATERIALS AND METHODS
Reagents and hormones. Dulbecco's modified Eagle's medium-F12 and Opti-MEM were obtained from GIBCO-BRL (Gaithersburg, MD). L-Glutamine, penicillin, and streptomycin were purchased from BioWhittaker (Walkersville, MD). Human neuromedin U-25 (hNMU-25) was purchased from Phoenix Pharmaceuticals (Belmont, CA). Mouse anti-hemagglutinin antibodies were from Roche Diagnostics (Mannheim, Germany). R(Ϫ)N6-(2-phenylisopropyl)adenosine (R-PIA), bovine serum albumin, forskolin, 3-isobutyl-1-methylxanthine, thrombin and other chemicals unless noted were obtained from Sigma Chemical (St. Louis, MO). R-PIA (1 mM) was prepared in dimethyl sulfoxide, whereas hNMU-25 and thrombin (300 M) were prepared in phosphate-buffered saline (GIBCO-BRL) as stocks. A dilution series of each ligand was made using the reaction assay buffer before use.
Construction of GPCRs and chimeric G protein plasmids. Human adenosine A1 receptor (AA1R; NM_000674), proteinase-activated receptor-1 (PAR-1; NM_001992), neuromedin U receptor-1 (NMUR1; NM_006056), and neuromedin U receptor-2 (NMUR2; NM_020167) cDNAs were amplified from human brain, ovary, placenta, and brain cDNA (Clontech, Palo Alto, CA), respectively. The products were subcloned into the pcDNA3.1/Zeo(ϩ) expression vector (Invitrogen Life Technologies, Carlsbad, CA) after sequence confirmation. Rat G s␣ with an internal hemagglutinin epitope tag ( 77 DVPDYA 81 ) in pcDNA1 (9), a gift from Dr. B. R. Conklin, was used as a template to replace its COOH-terminal five amino acids with those of other G␣ by the PCR-based mutagenesis. The PCR products were subcloned into the pcDNA3.1/Zeo(ϩ) expression vector, and the sequences were then confirmed. The reversed primer sequences corresponding to mutated five amino acids were as follows: GAAGAG-GCCACAGTC for G si/t/g, ATAAAGTCCACATTC for Gsi3, GAT-CAAGCCACAGCC for Gso; GCAAAGGCCGATGTA for Gsz; CT-GCAGCATGATATC for Gs12; CTGTAGCATAAGCTG for Gs13, CACCAGATTGTACTC for Gsq/11, GACAAGGTTGAATTC for Gs14, CAGCAGGTTGATCTC for Gs16, CAGCAGGTTGATC-TCGTC for Gs16-6, and TTCGTAGAGATTGAC for Gsc.
Protein detection and measurement of potential activities of chimeric G s proteins. To test the expression levels of the various chimeric G proteins, equivalent numbers (2 ϫ 10 6 ) of various chimeric Gs (1 g/ml)-transfected cells were lysed in the protein sample buffer. Measurement of the protein content was done using a Micro BCA protein assay kit (Pierce Biotechnology, Rockford, IL). A 50-g aliquot of each sample was analyzed by running a 12% SDS-PAGE. Western blotting was performed using mouse anti-hemagglutinin antibodies (Roche) or mouse anti-human ␤-actin (Chemicon International, Temecula, CA) followed by horseradish peroxidase-linked anti-mouse antibodies (Amersham Biosciences, Piscataway, NJ).
To demonstrate that all of the chimeric G proteins are able to activate adenylyl cyclases to the same degree, the chimeric G proteintransfected cells were further treated with or without AlF4 Ϫ (50 M AlCl3, 10 mM MgCl2, and 5 mM NaF) for 8 h (37). The cAMP amounts were measured in triplicate using a specific RIA (23) . Antibodies against cAMP were provided by the National Pituitary and Hormone Program.
Assessment of receptor activities based on cAMP production or inhibition or reporter gene activity. To assess the receptor activity stimulated by its corresponding agonists, confluent 293T cells in a 12-well plate were cotransfected with a receptor construct (1 g/well) together with each individual chimeric G s plasmid (30 ng/well) using LipofectAMINE 2000 (Invitrogen Life Technologies). A 33:1 plasmid ratio was chosen on the basis of the cAMP basal levels derived from transfected G s chimeras and the standard range of the cAMP RIA assay. To monitor the receptor-chimeric G protein coupling efficiency, receptor plasmids (1 g/well) together with increasing concentrations of chimeric G s constructs were used for the transfection. In addition, a certain amount of mock vector [pcDNA3.1/Zeo(ϩ)] was also added to maintain equal amounts of plasmids in each transfection. Then, 24 h after transfection, the cells were harvested using the cAMP assay buffer (DMEM-F12 supplemented with 0.1% bovine serum albumin and 0.25 mM 3-isobutyl-1-methylxanthine) and seeded onto a 24-well plate (2 ϫ 10 5 viable cells/ml). The transfected cells were then treated with different ligands for 8 h before measurement of the total cAMP levels in triplicate (23) .
For measuring cAMP amounts inhibited by the G i␣ pathways, NMUR1-or NMUR2-transfected 293T cells were resuspended in the cAMP assay buffer and seeded into a 24-well plate (2 ϫ 10 5 cells/well). The cells were preincubated with 100 nM hNMU-25 for 30 min and then stimulated by 1 M forskolin for 30 min. The cell medium was acetylated immediately, and this was followed by cAMP measurement in triplicates (23) .
For testing signal transduction mediated by the serum response element (SRE), 293T cells were cotransfected with an SRE-driven luciferase (SRE-Luc) reporter construct (Stratagene, La Jolla, CA) together with the NMUR1 or NMUR2 construct in the ratio 1:2. One day after transfection, cells were resuspended in DMEM-/F12 supplemented with 0.1% bovine serum albumin (5 ϫ 10 5 viable cells/ml) and treated with increasing doses of hNMU-25 for 16 h. Cells were harvested in the lysis buffer (Promega, Madison, WI), and the lysate was analyzed for luciferase activity using a luminometer (Bio-Rad Laboratories, Hercules, CA). Data are means Ϯ SE of triplicates (42) .
Assessing the tissue distribution of two NMURs. To analyze NMUR1 and NMUR2 mRNA expression, tissues were collected from four adult Sprague-Dawley rats, and total RNA was extracted using an RNeasy minikit (Qiagen Sciences, Valencia, CA). Total RNA from each sample was reverse transcribed for later PCR analysis. The specific primers were as follows: NMUR1 forward, GGCTTCAGT-GCTCAATGTCA; NMUR1 reverse, TAGCATCTTGGTCACCT-GTC; NMUR2 forward, AAGTACTTGAACAGCACAGAGGAGT; NMUR2 reverse, AGCTTGGATGATCAAGTTATACACC; ␤-actin forward, TGACAGACTACCTCATGAAGATCC; ␤-actin reverse, CTGCTTGCTGATCCACATCTG.
Data analysis. The cAMP data are presented as means Ϯ SE of triplicate measurements of triplicate cultures. The arbitrary units of luciferase activity varied between experiments and are presented as means Ϯ SD of triplicate determinations of a single experiment; two extra experiments showed similar results. Statistical significance was determined by ANOVA for multiple group comparisons. Significance was accepted at P Ͻ 0.05.
RESULTS
Hypothesis of the chimeric G protein array and design of the G s ␣ chimeras. G proteins have been classified into four subfamilies by their ␣-subunit composition: G s , G i , G 12 , and G q . Because of the diverse effectors for each subfamily (Fig. 1A,  top) , several distinct assays are needed to evaluate the different downstream pathways for a given GPCR (3, 31, 32) . In addition, concerns have been raised as to the choice of the wrong analytic approaches when monitoring an unknown GPCR response. G s ␣ but not any other G␣ directly activates adenylyl cyclases. Furthermore, the carboxyl termini of different G␣ subunits determine the specificity of receptor coupling (8, 9) . Based on these two facts, G s ␣ was chosen as a backbone to produce a set of chimeric G s ␣ expression vectors with various COOH-terminal replacements. We hypothesized that these G s ␣ chimeras would redirect the different G␣ pathways toward cAMP production. These G s ␣ chimeras would then allow one to dissect the ligand signaling for any given GPCR by simply measuring cAMP production (Fig. 1A, bottom) .
To prove our hypothesis, we constructed a set of chimeric G s ␣ proteins where the COOH-terminal five residues were replaced with those of other kinds. As shown in Fig. 1B , the chimera for the G s family, which contains G s and G olf , was designated G s/olf because of the identical COOH-terminal five residues between G s and G olf . Also, the chimeras for the G i family were designated G si/t/g (G i1 , G i2 , G t1 , G t2 , and G gust share the same COOH-terminal motif), G si3 , G so ,and G sz . The chimeras for the G 12 family included G s12 and G s13 , whereas the chimeras for the G q family contained G sq/11 (G q and G 11 share the same COOH-terminal motif), G s14 , and G s16 . In addition, a control chimera, G sc , with the COOH-terminal five amino acids of G q in random order was designed to demonstrate the specificity of interaction between the COOH terminus of chimeric G␣ and receptors. Each construct was transiently transfected into 293T cells individually, and the expression levels of chimeric G proteins were determined (Fig. 1B) . Compared with the loading control ␤-actin, all the G s chimeras were expressed at comparable levels except for the mock vector control. In addition, compared with the basal cAMP levels, the AlF4 Ϫ treatment increased cAMP production to a similar extent in each chimeric G protein-transfected cells (Fig.  1B, right) . These data suggest that all of the chimeric G proteins are able to activate adenylyl cyclases to the same degree.
Functional coupling of constructed chimeras to G i -, G 12 -, and G q -coupled GPCRs. To demonstrate the functional coupling of chimeric G s proteins to receptors, we transiently coexpressed either G si/t/g , G s12 , or G sq/11 chimera with a selected receptor, AA1R, PAR-1, or NMUR1, which have been reported to be able to couple to the G i (20) , G 12 (30) , or G q (16) family, respectively (Fig. 2) . In 293T cells cotransfected with AA1R and G si/t/g , R-PIA agonist treatment resulted in a dosedependent accumulation of cAMP ( Fig. 2A) . In contrast, R-PIA had no effect on cells transfected with AA1R only, AA1R with G sc ( Fig. 2A) , or G si/t/g only (data not shown), indicating that there was a successful coupling of the G si/t/g chimera to the G i -coupled receptor. To assess the coupling efficiency between G si/t/g and AA1R, cells were cotransfected with constant amounts of AA1R and graded doses of G si/t/g . The total amounts of plasmids used for transfection were adjusted to be equal, using a mock plasmid. The total cAMP concentrations in the samples with or without R-PIA (100 nM) stimulation were compared. As shown in Fig. 2B , an increase in basal cAMP was seen, corresponding to the transfected amount of G si/t/g . In the 0.01-0.3 g/ml range of G si/t/g , there was an increase of cAMP amount in the agonist-stimulated cells of 8.9 Ϯ 0.4-fold compared with cells without agonist treatment. The decrease in agonist-induced cAMP levels that occurred at the 1 g/ml G si/t/g point may be a result of the high cAMP background caused by overexpression of G si/t/g (Fig. 2B) . Therefore, in the following experiments for receptor pathway screening, a 33:1 plasmid ratio of GPCR to chimeric G s ␣ was used in consideration of the cAMP basal levels and unpredictable effects that occurred due to overexpression of G s chimeras.
PAR-1 and NMUR1 are known to be able to couple to the G 12 and G q pathways, respectively. Compared with receptor only, PAR-1 in the presence of G s12 or NMUR1 in the presence of G sq/11 can efficiently stimulate adenylyl cyclase activity in response to increasing concentrations of the corresponding agonists (Fig. 2, C and E) . Interestingly, no cAMP stimulation was observed in cells cotransfected with G sc and either receptor (Fig. 2, C and E) . The control G sc chimera is a functional construct because of its normal expression in the G sc -transfected cells (Fig. 1B) and the increasing cAMP background in cells transfected with graded amounts of G sc (data not shown). Fig. 1 . Hypothesis of the chimeric G protein array and design of the chimeric Gs␣ constructs. A: after G protein-coupled receptors (GPCRs) are activated, the corresponding G␣ subunits couple to the receptors using their COOH-terminal 5 amino acids as the interacting motif (8) . Top: effectors for the signaling responses vary with the various G␣ subunits that are activated. GEF, guanine-nucleotide exchange factor. Bottom: a set of Gs␣ chimeras (designated as Gsx, with x denoting the COOH-terminal origins from different G proteins where the COOH-terminal 5 amino acids were replaced by those of other G␣ was constructed to couple to diverse GPCRs, thus allowing switching of all receptor responses into the production of cAMP. This system can be used as a screening array for any given GPCR by simply measuring the cAMP accumulation under various stimulations (S1-Sn). B: alignment of COOH-terminal 5 amino acid sequences of G␣ subunits sorted by their subfamilies. Gsc, with the COOH-terminal sequence derived from the Gq but in random order, serves as a control chimera. Expression levels of the chimeric G proteins were determined by Western blotting using antibodies against the hemagglutinin tag on Gs␣. Western blotting against human ␤-actin served as a loading control. Each of the Gsx-transfected cells was further treated with AlF Ϫ 5 and fold increases of cAMP production were compared.
Therefore, these results suggest that the agonist-stimulated adenylyl cyclase activation is drawn from a specific coupling between the receptors and designed COOH termini of the chimeric G s proteins and are not because of the side reactions forced by the overexpression of either the receptors or the G s chimeras. In addition, the fold increase of cAMP production after agonist stimulation was reproducible in the 0.01-0.3 g/ml range of each chimeric G␣ construct (Fig. 2, D and F) . On the basis of sequence alignment, the sixth residue at the COOH termini of the different G␣ proteins is either Arg in G s , G o , and G 14 or Lys in G olf , G i1 , G i2 , G i3 , G z , G t1 , G t2 , G gust , G 12 , G 13 , G q , and G 11 , except for Asp in G 16 . To further identify whether the charge effect of Asp at the sixth residue of G 16 terminus might affect the receptor coupling, two G s16 chimeras with the G s COOH-terminal five-residue replacements, designated G s16 , or six-residue replacements, designated G s16-6 , were constructed. G 16 belongs to the G q family. Therefore, NMUR1, which is known to conduct Ca 2ϩ signals by activating PLC␤, was used for the coupling tests. In cells transfected with NMUR1 and graded doses of either G s16 or G s16-6 , increases in the cAMP basal levels were observed (Fig. 3) . However, in contrast to the cAMP background in cells without agonist stimulation, hNMU-25 elevated cAMP about sixfold in cells expressing NMUR1 and G s16 (Fig. 3A) as opposed to a less than 2.5-fold cAMP increase in cells expressing NMUR1 and G s16-6 (Fig. 3B) in the 0.01-0.3 g/ml range of the chimeric G protein constructs. These results suggest that more extensive replacements beyond the fifth position of G s ␣ COOH terminus do not further increase the coupling efficiency between G␣ proteins and corresponding receptors. Thus, the charge characteristics of the sixth residue at the G s ␣ COOH terminus may be involved in receptor interaction, maintenance of the G s ␣ conformation, or a yet unknown structural function(s).
Evaluation of AA1R coupling pathways using the chimeric G proteins. AA1R has been cloned and studied for more than 15 years, and its downstream coupling pathways have been well characterized (20) . Therefore, we chose AA1R to verify the ability and specificity of the G s chimeras for revealing G protein coupling preference. AA1R is known to be an adenylyl cyclase-inhibiting receptor that decreases cAMP production under cognate ligand stimulation (20) . Of interest, our data , and Gq-coupled NMUR1 (neuromedin U receptor-1; E andF) were chosen to evaluate functional couplings of chimeric Gsi/t/g, Gs12 and Gsq/11, respectively. R-PIA, R(Ϫ)N6-(2-phenylisopropyl) adenosine. To assess the concentration-associated response of the corresponding agonists, 293T cells were transfected with 1 g/ml receptor in the presence or absence of 30 ng/ml chimeric G protein.
After 24-h transfection, cells were treated with increasing amounts of ligands and then assayed for cAMP. In addition, cells cotransfected with receptors and Gsc were also stimulated with 100 nM agonist as a coupling control. To determine how coupling efficiency varied with graded doses of chimeric G proteins, 293T cells were cotransfected with the given receptor (1 g/ml) and increasing doses of chimeric G proteins (0 -1 g/ml). Amount of cAMP present was then determined after treatments with 100 nM of corresponding agonists or with cAMP assay buffer (buffer) only. Data are expressed as means of triplicates in 3 experiments Ϯ SE.
showed that the agonist R-PIA increased cAMP production in cells cotransfected with AA1R and various G s chimeras except wild-type G s/olf (Fig. 4 ) and G sc ( Fig. 2A) , suggesting that there is specific coupling between AA1R and other chimeric G s proteins.
In the chimeric G si family, our studies showed that there was an increase in cAMP production in cells cotransfected with AA1R and Gsi /t/g , G si3 , G so, or G sz of 8.9-, 8.0-, 3.9-, and 3.6-fold, respectively (Fig. 4) . In the chimeric G s12 family, cells coexpressing AA1R and either G s12 or G s13 , cAMP were increased 6.5-and 3.7-fold, respectively, after agonist stimulation. In addition to inhibiting cAMP accumulation, AA1R is also known to stimulate PLC␤ activity and arachidonate release (1). Our results showed that cells coexpressing AA1R and chimeric G s16 have a greater cAMP stimulation than those coexpressing AA1R and either G q/11 or G 14 in response to the agonist. These data suggest that AA1R is likely to have a greater preference for coupling to G 16 than to G q/11 or G 14 under intrinsic conditions.
Use of the set of G s chimeras as a tool to screen potential coupling pathways for receptors. It is well known that one GPCR can couple to several G protein pathways (29). There are also cases where a single ligand can activate several GPCRs but might regulate distinct biological functions in different tissues. Therefore, clarification of the coupling pathways of such receptors using a common ligand would help our understanding of their precise roles in the body. Neuromedin U (NMU), first reported in 1985 (25) , is a neuropeptide found to be able to activate two corresponding receptors, NMUR1 and NMUR2 (16) . We analyzed the mRNA distribution of two NMURs in 22 different rat tissues (Fig. 5) . In contrast to the wide distribution of the NMUR1 transcript, the NMUR2 message was found mainly in lung, duodenum, prostate, ovary, and uterus. These data imply potential differences of signaling between the two NMURs.
To screen their potential coupled G␣, either NMUR1 or NMUR2 was cotransfected with each chimeric G s , and the increasing fold in cAMP production was measured. Interestingly, NMUR1 and NMUR2 showed distinct differences in coupling to the various chimeric G proteins (Fig. 6 ). NMUR1 and NMUR2 showed no coupling to wild-type G s/olf under stimulation with NMU-25, indicating that neither of the receptors uses the G s pathway (Fig. 6, first condition) . In addition, no response was found in cells expressing the NMURs together with the control chimera G sc ( Fig. 2E for NMUR1 ; data not shown for NMUR2). These results suggest that the agoniststimulated cAMP production in the presence of NMURs and other G s chimeras is unlikely to be from a nonspecific effect because of overexpression of either the receptor or the G s chimera.
In the different G␣ subfamilies, no stimulation was induced by hNMU-25 when cells were cotransfected with NMUR1 and G si/t/g (Fig. 6A ). In addition, compared with the average response in the presence of G sq or G s12 members, only a low stimulating efficiency was observed in cells coexpressing NMUR1 and other G si members (G si3 , G so , or G sz ). However, NMUR1 strongly coupled to chimeric G sq members with various signal responses ranked G s14 Ͼ G sq/11 Ͼ G s16 (Fig.  6A ). NMUR1 also showed interaction with G s12 or G s13 in response to hNMU-25 with about a four-to fivefold increase in cAMP accumulation.
In contrast to NMUR1, NMUR2 after ligand stimulation coupled mainly to the G si family and increased cAMP production five-to ninefold in the ranking G sz Ͼ G si3 Ն G si/t/g Ͼ G o (Fig. 6B) . Similar to NMUR1, NMUR2 also coupled to G s12 and G s13 with an increase of about four-to fivefold in cAMP. However, unlike NMUR1, the signal couplings between NMUR2 and the G sq members were less effective. After treatment with hNMU-25, although a 6.6-fold increase was detected in cells coexpressing NMUR2 and G sq/11 , there was a less than threefold increase observed in cells coexpressing NMUR2 and either G s14 or G s16 . Therefore, although they were stimulated by a common agonist, our results suggest that NMUR1 and NMUR2 may play different physiological roles by activating diverse G protein pathways in the body. NMUR1 and NMUR2 preferentially activate different G␣ subtypes in intrinsic conditions. To assess the accuracy of pathway preference between NMUR1 and NMUR2 predicted by our chimeric G s proteins, the established assays for G i and G q signaling outputs were used. The inhibitory effect of forskolin-induced cAMP production is commonly used to evaluate the G i response. As shown in Fig. 7 , graded doses of hNMU-25 remarkably inhibited forskolin-induced cAMP production in the NMUR2-expressing cells, indicating that there was intrinsic G i coupling with NMUR2. In contrast, the inhibitory effect in response to hNMU-25 in the NMUR1-expressing cells was low to negligible.
The SRE-driven reporter gene assay has been used to evaluate the activation of GPCRs triggered by the G q and G 12 families via the changes in reporter gene levels (36) . In the presence of a SRE-Luc construct containing an SRE-driven luciferase, either NMUR1 or NMUR2 responded to hNMU-25 in a dose-dependent manner (Fig. 8) . However, the maximum stimulation of luciferase activity in NMUR1-transfected cells is four times higher than that in NMUR2-transfected cells (Fig.  8 ). In addition, no further stimulation was observed in cells transfected with an increasing amount of NMUR2 construct (data not shown). Though it is known that both G q and G 12 signals can link to SRE-dependent gene expression, our data using either chimeric G s12 or G s13 suggest that NMUR1 and NMUR2 have similar coupling efficiency to intrinsic G 12 or G 13 (Fig. 6) . Therefore, we conclude that the differences shown in the SRE-Luc reporter assay are derived from a higher coupling efficiency of the G q family to NMUR1 than to NMUR2 and is not caused by low expression levels of NMUR2.
DISCUSSION
G s proteins are highly conserved in mammals, with 99.7% identity between rats and humans. Taking advantage of the direct activation of adenylyl cyclases by G s , the present study develops a set of chimeric G s proteins for the evaluation of G protein coupling to GPCRs. In cells cotransfected with AA1R and G si/t/g , PAR-1 and G s12 , or NMUR1 and G sq/11 , we demonstrated that the chimeric G s proteins successfully redirect the endogenous G i , G 12 , or G q pathways into cAMP production. The lower cAMP stimulation in cells coexpressing G s16-6 and NMUR1 than in cells coexpressing G s16 and NMUR1 indicates the importance of the sixth residue at the G s COOH terminus for receptor coupling. Furthermore, the predictions for the endogenous pathways of AA1R, NMUR1, and NMUR2 by our G s chimeras demonstrate that this system is able to provide a new strategy for dissecting the concerto of multiple G protein couplings to any given GPCR. Such information would be undoubtedly invaluable when pharmaceutical assays and agents are being designed.
GPCRs, communicating signals from many neurotransmitters, hormones, chemokines, and environmental factors, are of particular interest when pharmaceutical screen design is carried out. However, the remarkable diversity and complexity of the couplings between GPCRs and G proteins raise difficulties for GPCR studies. From a drug screening perspective, it was our aim to create a generic technique with a very high likelihood for revealing the various GPCR-G protein interactions, which would allow high-throughput screening analyses. The discovery that the COOH-terminal tail of G␣ is the primary receptor recognition domain thus opens a new era of G protein receptor interaction study. Although numerous results have also suggested that various regions within G␣ subunits might act in concert to achieve interactions with receptors (7, 19) , so far, no receptors are able to couple to G␣ subunits without recognizing their COOH termini. In addition, our data also showed that no cAMP stimulation was observed when using the control G sc chimera (Fig. 2) , in which the COOH terminus was replaced by that of G q in a random order. Therefore, we conclude that the cAMP stimulations shown in the present study are derived from specific interactions between the receptors and the corresponding chimeric COOH termini of G s .
Degradation of cAMP is controlled by cAMP phosphodiesterase enzymes. In contrast to the difficulty in the detection of transient Ca 2ϩ mobilization, measuring cAMP production is a much more accessible assay, especially when a nonselective inhibitor such as 3-isobutyl-1-methylxanthine is added during the reaction to block phosphodiesterase activity. In addition, although several G q or G 16 chimeras with certain COOHterminal modification have been studied (8, 26) , no systematic chimeric G protein set has been proposed for pathway screening and orphan GPCR studies. Our proposed chimeric G protein array with systematic COOH-terminal replacements should be able to compensate for the inadequacies of the previous promiscuous system when capturing overall GPCR responses. In the present results, although only several G s -inactive receptors were chosen to display the GPCR interactions with chimeric G s proteins, future studies using G s -null cell lines will eliminate endogenous G s problems, thus allowing the application of pathway screening to intrinsic G s -coupled GPCRs.
AA1R is widely distributed in the body and modulates many physiological functions, including a decrease in heart rate and atrial contractility (17) , the control of neurotransmission (34) , and the regulation of hepatic glycogen metabolism, as well as a reduction of lipolysis in adipose tissue (10, 12) . AA1R has been reported to show higher intrinsic activity on activation of G i1 , G i2 , and G i3 than of G o , This study indicates that G icoupled pathways may be activated selectively by AA1R (22, 28) , consistent with our results shown in cells cotransfected with AA1R and Gsi /t/g , G si3 , or G so chimeras. Each chimera is different merely at the COOH terminus, and therefore our data demonstrated that the members of chimeric G si family were able to be used to evaluate the G i -coupling preference of AA1R. Although no study has clearly reported the direct coupling of AA1R to G z , our results showed that there was an interaction between AA1R and G sz . Similar interactions have been also reported in previous studies when AA1R was coexpressed with G q or G 16 chimeras fused with the G z COOH terminus (8, 26) . In addition, AA1R has been reported to induce stress fiber formation and inhibit neurite process formation through Rho-mediated pathways (38) , supporting the intrinsic interaction between AA1R and the G 12 family predicted in our results. Furthermore, a recent study has proved that there is a direct interaction between AA1R and G 16 in the NF-B-mediated anti-inflammatory action (21) , indicating that AA1R would stimulate the PLC␤ pathway with a greater coupling preference to G 16 than to G q/11 or G 14 . Similar results were also found in our studies in the chimeric G sq family. Though AA1R has been reported to interact with many G␣ proteins, it is difficult to compare their coupling preference using different reading outputs. The chimeric G s ␣ system, to our knowledge, is the first tool that can reveal the G␣-coupling preference of AA1R under the same platform.
There are many examples that a common agonist can activate several receptors. However, it is difficult to explain the natural design of multiple receptors without knowing the differences in their downstream signal conduction. Two NMURs, for example, were found to be activated by NMU, a neuropeptide with potent activity affecting smooth muscle contraction, blood pressure increase, stress response, and animal feeding (6, 16, 25) . However, unlike NMU, which is widely expressed in tissues (2, 15) , NMUR1 expression is abundant in peripheral tissues whereas NMUR2 is expressed chiefly in the central nervous system (16, 33) . The differences in distribution and/or signals between NMUR1 and NMUR2 ought to contribute to their functional diversities. Although the interaction between NMU and the two receptors can be monitored by measuring intracellular Ca 2ϩ and inositol phosphate accumulation (16, 33) , neither method is able to distinguish the detailed differences in signaling between NMUR1 and NMUR2. In contrast, when we used chimeric G proteins, our results revealed that there is a distinct preference in G protein selectivity between NMUR1 and NMUR2, which supports the functional diversity of NMU in various tissues by activating different receptors through diverse G protein pathways. From a pharmaceutical perspective, this information may allow one to develop smallmolecule agonists or antagonists with receptor subtype specificity that will help to identify the roles of NMU as well as the receptor subtypes through which the different effects are mediated. Likewise, similar approaches can also be applied to other receptors. In addition, it is known that several NMU isoforms can be produced either by posttranslational cleavage of a preprohormone (25) or by individual gene transcription (27) . It would be interesting to explore whether the different NMU isoforms are able to alter receptor selectivity on G protein coupling.
Furthermore, it is well known that some GPCRs are able to interact with more than one endogenous agonist. Although no example was studied here, the application of a whole set of G s chimeras should be able to reveal the differences in G protein selectivity associated with a certain receptor when stimulated by diverse agonists. Interestingly, a diverse spectrum of G protein-coupled pathways has been found to show receptor properties with different ligand selectivity (4, 24, 35 ). An example is the human serotonin 2C receptor, where it has been shown that certain agonists can preferentially activate the PLC␤-IP 3 pathway, whereas other agonists favor the phospholipase A 2 -arachidonic acid release pathway (4). These results strongly support the "agonist-directed trafficking of receptor stimulus" hypothesis proposed by Kenakin (18) . It has been hypothesized that each different agonist-receptor interaction stabilizes a unique conformation of the receptor, which changes its specificity for different G proteins (24) . If agonistdirected trafficking occurs, the physiological outcome of receptor activation may change depending on which endogenous ligand is seen by a receptor. However, the available information is inadequate, and the underlying mechanism remains speculative, partially because it is difficult to normalize the G protein coupling efficiency from different reading outputs against various G␣ responses. In contrast, our proposed chimeric G s ␣ analyses should provide a convenient tool to compare the G protein-coupled preferences of a given GPCR when stimulated with different agonists. This could provide important information on physiological as well as pharmacological regulation. Similarly, in drug design, therapeutic agents could be developed with even greater selectivity than now afforded, by exploiting selective affinity for a subclass of receptor pathways and thus minimizing unwanted effects.
The chimeric G s proteins will be also useful for orphan GPCR studies. Up to the present, no single G␣ or its chimera can serve as a universal signaling adaptor for all different receptors because of the unique COOH-terminal characteristics of G␣ that provide a limited range for receptor selectivity. With a whole set of chimeric G s proteins designed to cover all G␣ subtypes, it should be possible to redirect orphan GPCRs with unknown G protein-coupling specificities toward a common cAMP assay end point. This approach can avoid the need to set up different assays for agonist screening.
In conclusion, the present study provides a comprehensive and convenient approach to explore previously uncharacterized G protein pathways for GPCRs with known ligands. Besides, the present chimeric G s protein system can serve as a tool to examine the potential G protein pathways for orphan GPCRs, thus allowing future screening of candidate ligands. With the rapid progress in high-throughput screening and real-time techniques using live cells with fluorescent probed molecules (11, 14) , one can envisage that this novel system is likely to be incorporated into drug discovery programs.
